Search

everythinglearnresearchcommunity

for

Search:↓

The user was diagnosed with DUPA and initially treated with finasteride, then switched to dutasteride which worsened their hair loss. They are now returning to finasteride and adding treatments including oral minoxidil, Proscar, Viviscal, pumpkin seed oil, LLLT, and Nizoral shampoo, hoping for hair regrowth.

The conversation is about whether a doctor is needed for injections of a product called SCUBE3 for hair loss. No specific treatments were discussed.

The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

The conversation is about making topical finasteride with stemoxydine, including questions on dosages, bulk preparation, and storage.

A new product, Minoxidil booster, which enhances sulfotransferase enzyme activity in the scalp, is now available. The user has started using this product, applied before Minoxidil, to improve their hair loss treatment results.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The user has been using minoxidil, trioxidil, procapil, redensyl, and ashwagandha lotion for hair loss but can't find more procapil redensyl lotion. They are seeking advice on where to find it or alternative solutions.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.

User "Number_Worried00" is using a treatment stack for hair loss, including Minoxidil, Finasteride, Dutasteride, Estradiol, Cetirizine, and Pyrilutamide. Another user suggests that if the cause is vitamin deficiency or inflammation, the stack may not be effective.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

User wants to try procyanidin b2 and broccoli sprouts sulforaphane for hair loss and asks for supplement suggestions. Replies suggest taking fin by asteride and growing sprouts in mason jars to eat raw.

Saw palmetto, a 5-alpha reductase inhibitor, caused unexpected side effects like breast changes and altered semen consistency, which resolved after stopping its use. Concerns about similar side effects with finasteride or dutasteride were expressed, and another user reported low libido and depression from saw palmetto.

A user beginning a treatment of pyrilutamide for hair loss, which they plan on updating progress on every month.

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The user reported significant hair regrowth and stopped hair loss after using Pyrilutamide and Minoxidil for four months. They found Pyrilutamide effective in blocking DHT locally without side effects, preferring a gray market version over Koshine's product.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

The conversation is about finding a reliable source to purchase Pyrilutamide that ships to the UK. There's also an openness to using RU58841 as an alternative.

The user has been mixing finasteride with stemoxydine for hair loss and is considering switching to a less expensive product with a different ingredient list. They are questioning if the new product's higher water content compared to alcohol will affect the finasteride's solubility.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.